ChemoCentryx, Inc. (CCXI) News
Filter CCXI News Items
CCXI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CCXI News Highlights
- For CCXI, its 30 day story count is now at 5.
- Over the past 13 days, the trend for CCXI's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- LI, AMGN and UL are the most mentioned tickers in articles about CCXI.
Latest CCXI News From Around the Web
Below are the latest news stories about CHEMOCENTRYX INC that investors may wish to consider to help them evaluate CCXI as an investment opportunity.
ChemoCentryx shareholders approve $4.7B merger with Amgen
|
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned presentations covering TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, at the American Society of Nephro |
Is ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?Here is how ChemoCentryx (CCXI) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year. |
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced two upcoming poster presentations for CCX559, the Company’s investigational, highly potent, orally administered PD-L1 checkpoint inhibitor, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meet |
Why Is Ionis Pharmaceuticals (IONS) Down 5.8% Since Last Earnings Report?Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Why Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report?ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
7 Dow Stocks With Superior FundamentalsWhile investors look for safe bets, here are seven Dow stocks to buy in September. |
These 10 Non-Covid Biotech Stocks Are Up 40% Or More This YearBiotech stocks are scorching right now. But the best of the best have strong gains. Those include 10 with at least 40% growth this year. |
ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical ConferencesSAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned poster presentations at three upcoming medical conferences taking place in August and September, which highlight TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and its role in ANCA-associated vasculitis, as well as the role of C5a and C5aR in severe hidradenitis suppurativa (HS) and lupus nephritis (LN). 18th European Meeting on Complem |
Here's Why ChemoCentryx (CCXI) is a Great Momentum Stock to BuyDoes ChemoCentryx (CCXI) have what it takes to be a top stock pick for momentum investors? Let's find out. |